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ABSTRACT In recent years, several cases pointing at sacroiliitis due to isotreti-
noin treatment have been reported, but a causal association remains unprov-
en. The aim of this study was to assess the characteristics of patients in whom 
bilateral sacroiliitis was detected while using isotretinoin treatment for acne 
and to review previous sacroiliitis cases treated with isotretinoin. In total, 11 
patients who were diagnosed with sacroiliitis during isotretinoin treatment 
were identified, and patient characteristics were noted. Patients were classified 
according to magnetic resonance imaging (MRI) findings. The 11 patients (3 
men and 8 women) ranged in age from 16 to 37 years (mean age 24.27 years). 
All the 11 (100.00%) patients presented with hip pain, which in 3 (27.27%) pa-
tients started in the first month, in 3 (27.27%) in the second, in 2 (18.18%) in 
the third, in 2 (18.18%) in the fourth, and in 1 (9%) in the fifth. HLA-B27 (human 
leucocyte antigen) was negative in all cases. MRI findings confirmed mild bi-
lateral sacroiliitis in 5 (45.45%) patients, moderate in 3 (27.27%), and severe in 
2 (18.18%).  Although our study included a small number of cases, it indicates 
a strong association between isotretinoin and sacroiliitis. 
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INTRODUCTION
Isotretinoin, a synthetic analogue of vitamin A 
that has been prescribed to many acne patients 
worldwide, has some known and well-described se-
vere adverse effects (1). However, the onset of bilat-
eral sacroiliitis during isotretinoin use has only been 
reported in a few case reports; therefore, the risk has 
not been assessed (2-13). The aim of this study was 
to retrospectively examine the patients who were di-
agnosed with bilateral sacroiliitis while being treated 
with isotretinoin to clarify the association between 
isotretinoin and bilateral sacroiliitis.
PATIENTS AND METHODS
In this study, patients admitted to our Dermatol-
ogy and Physical Therapy Clinic and Rehabilitation 
Clinic between January 2011 and January 2015 were 
evaluated. Eleven patients who developed bilateral 
sacroiliitis during systemic isotretinoin treatment for 
nodulocystic acne were analyzed retrospectively. For 
each patient, age, sex, dose of the isotretinoin treat-
ment, time of initial arthralgia symptoms, erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP), 
and human leucocyte antigen (HLA)-B27 results, 
and therapies used for sacroiliitis were recorded. MRI 
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findings with coronal, oblique, and axial T1, T2, and 
fat-saturation T2 sequences of the sacroiliac joints 
were assessed. Magnetic resonance imaging (MRI) 
scans were scored using the semi-quantitative Leeds 
Scoring System, in which bone marrow edema is grad-
ed from 1 to 3 (1=<25% of quadrant affected; 2=25-
75% of quadrant affected; and 3=>75% of quadrant 
affected) according to the severity of the sacroiliitis. 
Patients were classified as having mild, moderate, or 
severe sacroiliitis using bone marrow edema grades 
of 1, 2, or 3, respectively.
RESULTS
In total, 11 patients with acne vulgaris who pre-
sented with bilateral sacroiliitis during isotretinoin 
treatment were included in this study (Table 1). None 
of the patients had acne fulminans or acne conglo-
bata. The ages of the patients ranged from 16 to 37 
years, with a mean age of 24.27 years. The number of 
men and women was 3 (27.27%) and 8 (72.72%), re-
spectively. The initial dose of isotretinoin was 30 mg 
for the first month, and it was then increased to 40 
mg/day for the following months for every patient. 
All 11 (100.00%) patients presented with bilateral 
hip joint pain and were classified as the inflamma-
tory type. The hip pain started in the first month in 
3 (27.27%) of the cases, in the second month in 3 
(27.27%) cases, in the third in 2 (18.18%) cases, in the 
fourth in 2 (18.18%) cases, and in the fifth month in 1 
(9.00%) case. All patients were negative for antinucle-
ar antibodies, rheumatoid factor, and C3 and C4 tests. 
HLA-B27 was negative in all cases, and ESR and CRP 
levels were within normal limits. No patients had per-
sonal or family history of arthritis, and two of the pa-
tients reported back pain while one patient reported 
previous mild pain in the knees. MRI confirmed grade 
1 bilateral sacroiliitis in 5 (45.45%) patients, grade 2 
in 3 (27.27%) patients, and grade 3 in 2 (18.18%) pa-
tients (Figure 1). The severity of sacroiliitis was cate-
gorized as mild in 5 (45.45%) patients, moderate in 3 
(27.27%) patients, and severe in 2 (18.18%) patients. 
Isotretinoin treatment was discontinued when the 
diagnosis of sacroiliitis was established. All patients 
were started on indomethacin at 150 mg/day. In 10 
(90.90%) patients, laboratory results confirmed the 
symptoms had almost completely resolved within 
one month. Hip joint pain continued in one female 
patient (patient 10) with a personal history of recur-
ring aphthous ulcers. Patient 10 developed painful 
genital ulcers on the labia minora, which resolved 
with scarring and superficial thrombophlebitis on 
the forearm within a month of the diagnosis of bilat-
eral sacroiliitis. Pathergy test was negative, and the 
patient was diagnosed with Behcet’s disease and was 
started on a treatment of colchicine at 150 mg/day 
and diclofenac sodium at 150 mg/day with gradual 
improvements over four months. Diclofenac sodi-
um was discontinued in the fourth month after the 
symptoms of sacroiliitis completely resolved, and the 
patient continued colchicine therapy. Based on the 


















1 22/F 20-40 mg/day 4 months 19/0.04 - 1/ Mild Indomethacin -
2 16/M 20 mg/day 1 month 4/0.01 - 2/ Moderate Indomethacin -
3 25/F 20-40 mg/day 3 months 17/1.3 - 2/ Moderate Indomethacin Knee pain
4 32/F 20-40 mg/day 3 months 6/1.23 - 1/ Mild Indomethacin Back pain
5 24/F 20-40 mg/day 2 months 19/0.30 - 1/ Mild Indomethacin -
6 19/F 20 mg/day 1 month 16/0.72 - 1/ Mild Indomethacin -
7 17/M 20-40 mg/day 4 months 11/0.52 - 2/ Moderate Indomethacin Back pain
8 21/F 20-40 mg/day 2 months 27/0.48 - 3/ Severe Indomethacin -
9 37/F 20-40 mg/day 2 months 16/0.10 - 3/ Severe Indomethacin -




11 18/M 20 mg/day 1 month 13/0.30 - 1/ Mild Indomethacin -
*F: female; M: male; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; HLA: human leucocyte antigen
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5 months 45/36.00 - X-ray-CT: Widening and erosion 
of sacroiliac joints, scintigraphy: 






M/17 30 mg/day days ↑/↑ - X-ray-CT: Widening and erosion 




Geller et al. M/18 40 mg/day 1 month - - Scintigraphy: Light bilateral 
sacroiliitis
NSAID
Elias et al. M/17 0.5 mg/kg/
day








12 days 30/93.40 - Scintigraphy: Bilateral 
sacroiliitis




Dincer et al. M/18 25 mg/day 3 months 87/48.20 - Scintigraphy: Increased uptake 
of right sacroiliac joint, MRI: 
Bone marrow edema
NSAID
F/25 - 2 years 10/5 - Scintigraphy: Increased 
uptake on sacroiliac joints, CT: 
Increased sclerosis
-



















8 weeks after 
6 months of 
isotretinoin







F/31 - 3 months 11/0.13 - MRI: Bone marrow edema Indomethacin
M/16 - 11 months 8/0.05 - MRI: Sclerosis Indomethacin
M/22 - 24 months 23/1.10 - MRI: Sacroiliitis Indomethacin
F/19 - 3 months 2/0.80 - MRI: Bone marrow edema Indomethacin





3 months 69/24.00 - MRI: Moderate to severe 
sacroiliitis with joint effusions 
and florid bone marrow edema 
in the sacroiliac joints
Naproxen
Rozin et al. E/28 30 mg/day 20 days 35/1.3 - Scintigraphy: Increased uptake 





*M: male; F: female; NSAID: non-steroid anti-inflammatory drugs; ESR: erythrocyte sedimentation rate; CRP: C-reactive 
protein;
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chronology of events and the improvement of the 
sacroiliitis after the discontinuation of isotretinoin in 
all our patients, sacroiliitis is associated with isotreti-
noin treatment.
DISCUSSION
For severe acne, arthralgia was noted in 16% of 
patients during treatment with systemic isotretinoin 
(14). Acne fulminans is a rare condition characterized 
by the abrupt onset of nodular acneic and ulcerative 
lesions, which may be accompanied by fever, arthral-
gias, myalgias, and osteolytic lesions (15). The SAPHO 
(synovitis, acne, pustulosis, hyperostosis, osteitis) 
syndrome is considered a member of the spondylo-
arthropathy family, which may present with unilateral 
or bilateral sacroiliitis (16). Acne conglobata may also 
be associated with the musculoskeletal symptoms of 
arthralgia and arthritis (17). Five of the reported pa-
tients with sacroiliitis during isotretinoin treatment 
were classified as acne fulminans, however it is not 
clear whether isotretinoin caused sacroiliitis or if sac-
roiliitis is a systemic symptom of an acne fulminans 
flare (2-6). In our study, no patients were diagnosed 
with sacroiliitis due to acne fulminans, acne congloba-
ta, or SAPHO syndrome because sacroiliitis appeared 
after isotretinoin treatment without any increases of 
systemic symptoms related to these diseases and it 
resolved after withdrawal of the drug. Isotretinoin is 
suggested to be responsible for the systemic symp-
toms of patients with acne fulminans due to the in-
creased fragility of the pilosebaceous epithelium and 
the massive contact with Propionibacterium acnes an-
tigens, leading to exaggerated hypersensitivity reac-
tion types III and IV (18). Altered neutrophil function 
in the predisposed patients with hyper-reactivity to 
inflammatory mediators and decreased phagocytosis 
of propionibacterium acne is also another theory re-
garding the induction of acne fulminans (18).
Arthritis that is mild in severity and disappears 
without sequelae has been reported in a few cases 
involving mono or oligo arthritis of the hip, knee, an-
kle, shoulder, elbow, wrist, and finger joints (17-22). 
An adult onset Still’s disease triggered by isotretinoin 
treatment of acne conglobata has been noted as well 
(23). Immune dysfunction occurs in patients using 
isotretinoin, with possible mechanisms and pathways 
leading to arthritis and vasculitis (18). Because of its 
detergent-like properties, isotretinoin induces some 
alterations in the lysosomal membrane structure of 
the cells, facilitating a cytopathic destruction of the 
synovial cells and making the structure sensitive to 
mechanical irritation (18). Matsuoka et al. measured 
the isotretinoin concentration (131 ng/mL) obtained 
from the synovial fluid of a patient’s knee, confirm-
ing the drug caused the arthritis (18). Gene polymor-
phisms of retinoic acid receptor alpha genes in the 
frequencies of CTG, TTG, and TTT haplotypes are sug-
gested to be associated with arthralgia of patients us-
ing isotretinoin, which makes some people prone to 
rheumatologic side-effects (24). Dincer et al. reported 
two cases – a football and a basketball player – with 
sacroiliitis during isotretinoin treatment, indicating 
the relation between mild trauma and arthritis (7). 
None of our patients were interested in sports.
In our literature search, 18 patients (13 men, 5 
women) with isotretinoin-induced sacroiliitis were 
observed to up to now (Table 2) (2-13). In our study, 
sacroiliitis was observed mostly in women. Among 
these, 3 cases had unilateral and 10 cases had bilat-
eral sacroiliitis, though the laterality of 5 cases was 
not mentioned in the related report (2-13). Ages 
ranged between 14 and 31 years, and the mean age 
was 20.44 years. The time of initial symptoms of sac-
roiliitis after administration of isotretinoin differed 
between a few days and 2 years (2-13). HLA- B27 was 
found to be positive in 3 cases (7-9). Eksioglu et al. 
noted the patients with HLA-B27 positivity could be 
susceptible to developing sacroiliitis during isotreti-
noin treatment (8). We did not observe the HLA-B27 
positivity in any patients. X-ray, computed tomogra-
phy scan, bone scintigraphy, and MRI were used for 
the detection of sacroiliitis (2-13). An MRI of the sac-
roiliac joints has become a valuable tool for the early 
diagnosis of sacroiliitis in patients with inconclusive 
radiographic findings (25). Positive MRI findings have 
Figure 1. Oblique coronal plane fat saturation T1-weighted 
MRI image of the sacroiliac joints demonstrating bilateral 
bone marrow edema.
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been reported to have the same significance as a 
positive test for HLA-B27 (25). Hermann et al. showed 
the MRI may reveal both active and structural signs of 
sacroiliitis, while conventional radiography and com-
puted tomography only demonstrate structural or 
chronic changes (25). The improvement in the sacroi-
liitis of our patients is visible through the resolution 
of symptoms. In fact, confirmation with radiological 
imaging after resolution of the symptoms is suggest-
ed by authors (11). In the present study, the clinical 
findings of Behcet’s disease appeared in one patient 
during isotretinoin treatment. Sacroiliitis has been 
observed in 6% of patients with Behcet’s disease (26). 
Whether the drug triggered sacroiliitis or if sacroili-
itis is an articular manifestation of Behcet’s disease 
remains unclear in this case. In most cases (10/18) in 
the literature, the clinical symptoms were self-limited 
and resolved after isotretinoin was discontinued and 
non-steroid anti-inflammatory drugs (NSAID) were 
administered (4,7,8,11). All our patients except one 
with Behcet’s disease improved within a month after 
isotretinoin had been discontinued. Bachmeyer et al. 
returned patients to isotretinoin therapy a few weeks 
after withdrawal at a dose of 0.1 mg/kg/day, but a re-
lapse of pain occurred 48 h later. However, they con-
tinued treatment in combination with prednisolone 
and then increased the isotretinoin dose to 0.5 mg/
kg/day (2). Zanelato et al. also restarted isotretinoin 
with prednisolone after 30 days of withdrawal (6). 
Yılmazer et al., Elias et al., and Bachmeyer et al. treated 
patients with prednisolone (15 mg/day, 30 mg/day, 
30 mg/day, respectively) in addition to diclofenac so-
dium for 6 weeks (9). Tasdelen et al. and Barbareschi 
et al. used sulfasalazine added to prednisolone and 
anti-inflammatory drugs for remission (3,10).
CONCLUSIONS
Not enough cases have yet been reported to 
determine whether there is a true association be-
tween isotretinoin and sacroiliitis, but dermatologists 
should be aware of the rheumatologic symptoms of 
the patients. Recent data from the literature confirm 
the discontinuation of the drug and administration of 
anti-inflammatory drugs result in an almost complete 
resolution of the symptoms. The role and mechanism 
of isotretinoin as a causative factor in sacroiliitis must 
be investigated further.
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